Annual Cash & Cash Equivalents
$76.68 M
-$32.23 M-29.60%
December 31, 2023
Summary
- As of February 8, 2025, ATNM annual cash & cash equivalents is $76.68 million, with the most recent change of -$32.23 million (-29.60%) on December 31, 2023.
- During the last 3 years, ATNM annual cash & cash equivalents has risen by +$13.12 million (+20.64%).
- ATNM annual cash & cash equivalents is now -29.60% below its all-time high of $108.91 million, reached on December 31, 2022.
Performance
ATNM Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$78.66 M
-$7.38 M-8.57%
September 30, 2024
Summary
- As of February 8, 2025, ATNM quarterly cash and cash equivalents is $78.66 million, with the most recent change of -$7.38 million (-8.57%) on September 30, 2024.
- Over the past year, ATNM quarterly cash and cash equivalents has increased by +$1.98 million (+2.59%).
- ATNM quarterly cash and cash equivalents is now -32.38% below its all-time high of $116.33 million, reached on June 30, 2022.
Performance
ATNM Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ATNM Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -29.6% | +2.6% |
| 3 y3 years | +20.6% | -4.1% |
| 5 y5 years | +460.8% | +449.6% |
ATNM Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.6% | at low | -32.4% | +9.2% |
| 5 y | 5-year | -29.6% | +728.6% | -32.4% | +1223.8% |
| alltime | all time | -29.6% | >+9999.0% | -32.4% | -100.0% |
Actinium Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $78.66 M(-8.6%) |
| Jun 2024 | - | $86.04 M(+2.4%) |
| Mar 2024 | - | $84.06 M(+9.6%) |
| Dec 2023 | $76.68 M(-29.6%) | $76.68 M(-7.6%) |
| Sep 2023 | - | $82.98 M(-9.1%) |
| Jun 2023 | - | $91.28 M(-3.4%) |
| Mar 2023 | - | $94.52 M(-13.2%) |
| Dec 2022 | $108.91 M(+39.9%) | $108.91 M(-2.6%) |
| Sep 2022 | - | $111.81 M(-3.9%) |
| Jun 2022 | - | $116.33 M(+61.5%) |
| Mar 2022 | - | $72.02 M(-7.5%) |
| Dec 2021 | $77.83 M(+22.4%) | $77.83 M(-5.1%) |
| Sep 2021 | - | $82.03 M(+0.1%) |
| Jun 2021 | - | $81.91 M(+13.4%) |
| Mar 2021 | - | $72.25 M(+13.7%) |
| Dec 2020 | $63.56 M(+586.8%) | $63.56 M(+31.8%) |
| Sep 2020 | - | $48.23 M(-9.8%) |
| Jun 2020 | - | $53.47 M(+799.8%) |
| Mar 2020 | - | $5.94 M(-35.8%) |
| Dec 2019 | $9.25 M(-32.3%) | $9.25 M(-35.3%) |
| Sep 2019 | - | $14.31 M(-26.7%) |
| Jun 2019 | - | $19.52 M(+96.7%) |
| Mar 2019 | - | $9.92 M(-27.4%) |
| Dec 2018 | $13.67 M(-21.4%) | $13.67 M(-7.6%) |
| Sep 2018 | - | $14.81 M(-31.1%) |
| Jun 2018 | - | $21.47 M(-19.8%) |
| Mar 2018 | - | $26.76 M(+53.8%) |
| Dec 2017 | $17.40 M(-15.2%) | $17.40 M(-15.3%) |
| Sep 2017 | - | $20.54 M(+79.3%) |
| Jun 2017 | - | $11.46 M(-33.0%) |
| Mar 2017 | - | $17.09 M(-16.7%) |
| Dec 2016 | $20.52 M(-20.0%) | $20.52 M(+32.1%) |
| Sep 2016 | - | $15.53 M(-24.1%) |
| Jun 2016 | - | $20.46 M(-7.9%) |
| Mar 2016 | - | $22.21 M(-13.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $25.64 M(+282.3%) | $25.64 M(+3.6%) |
| Sep 2015 | - | $24.76 M(-4.6%) |
| Jun 2015 | - | $25.95 M(+34.6%) |
| Mar 2015 | - | $19.29 M(+187.5%) |
| Dec 2014 | $6.71 M(+21.2%) | $6.71 M(-42.9%) |
| Sep 2014 | - | $11.75 M(-19.9%) |
| Jun 2014 | - | $14.67 M(+149.6%) |
| Mar 2014 | - | $5.88 M(+6.2%) |
| Dec 2013 | $5.53 M(-1.5%) | $5.53 M(+38.7%) |
| Sep 2013 | - | $3.99 M(-29.4%) |
| Jun 2013 | - | $5.65 M(+74.4%) |
| Mar 2013 | - | $3.24 M(-42.3%) |
| Dec 2012 | $5.62 M(-1.5%) | $5.62 M(>+9900.0%) |
| Sep 2012 | - | $0.00(-100.0%) |
| Jun 2012 | - | $100.00(0.0%) |
| Mar 2012 | - | $100.00(-100.0%) |
| Dec 2011 | $5.70 M(>+9900.0%) | $5.70 M(>+9900.0%) |
| Sep 2011 | - | $100.00(0.0%) |
| Jun 2011 | - | $100.00(0.0%) |
| Mar 2011 | - | $100.00(0.0%) |
| Dec 2010 | $100.00(-95.2%) | $100.00(0.0%) |
| Sep 2010 | - | $100.00(-50.0%) |
| Jun 2010 | - | $200.00(-83.3%) |
| Mar 2010 | - | $1200.00(-42.9%) |
| Dec 2009 | $2100.00(-4.5%) | $2100.00(0.0%) |
| Sep 2009 | - | $2100.00(-4.5%) |
| Jun 2009 | - | $2200.00(0.0%) |
| Mar 2009 | - | $2200.00(0.0%) |
| Dec 2008 | $2200.00(-4.3%) | $2200.00(0.0%) |
| Sep 2008 | - | $2200.00(-4.3%) |
| Jun 2008 | - | $2300.00(0.0%) |
| Mar 2008 | - | $2300.00(0.0%) |
| Dec 2007 | $2300.00(+360.0%) | $2300.00(-64.1%) |
| Sep 2007 | - | $6400.00(+1180.0%) |
| Jun 2007 | - | $500.00(0.0%) |
| Dec 2006 | $500.00 | $500.00 |
FAQ
- What is Actinium Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Actinium Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Actinium Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of ATNM is $76.68 M
What is the all time high annual cash & cash equivalents for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high annual cash & cash equivalents is $108.91 M
What is Actinium Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, ATNM annual cash & cash equivalents has changed by -$32.23 M (-29.60%)
What is Actinium Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ATNM is $78.66 M
What is the all time high quarterly cash and cash equivalents for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high quarterly cash and cash equivalents is $116.33 M
What is Actinium Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, ATNM quarterly cash and cash equivalents has changed by +$1.98 M (+2.59%)